Why Moderna Stock Jumped Today
Shares of Moderna (NASDAQ: MRNA) rose by 6.5% on Thursday after the biotech said it had collected enough data from the phase 3 study of its experimental COVID-19 vaccine to trigger an interim analysis.
Moderna said enough people in its clinical trial had contracted COVID-19 for the independent Data Safety Monitoring Board (DSMB) to begin a review of the effectiveness of its coronavirus vaccine candidate, mRNA-1273.
Moderna's stock climbed on Thursday as investors looked ahead to a potentially positive outcome for its phase 3 trial of mRNA-1273. Image source: Getty Images.
Source Fool.com
